Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04313504 · ClinicalTrials.gov registry record · Phase 2

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

A Phase 2 study of Head and Neck Cancer, sponsored by Trisha Wise-Draper.

Active
Registry status
Phase 2
Development phase
23
Enrollment target
1
Study location

NCT04313504: Active Phase 2 study of Head and Neck Cancer, sponsored by Trisha Wise-Draper.

NCT04313504 is a Phase 2 study of Head and Neck Cancer that is active but no longer recruiting, run by Trisha Wise-Draper. The registered enrollment target is 23 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04313504, a Phase 2 study of Head and Neck Cancer, is active but no longer recruiting, sponsored by Trisha Wise-Draper.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the best overall response of the combination of dostarlimab and niraparib in patients with recurrent and/or metastatic HNSCC patients.

Primary Outcome

Measured by assessing best overall response using RECIST 1.1 in subjects in recurrent and/or metastatic HNSCC patients receiving combination of niraparib and dostarlimab.

Conditions Studied

Head and Neck Cancer

Interventions

  • DRUG Niraparib
  • DRUG Dostarlimab

Study Locations (1)

Ohio

  • University of Cincinnati Medical Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2020-11-04
Est. Completion 2025-06-01
Phase Phase 2
Trisha Wise-Draper

6 total trials

What the registry record for NCT04313504 still lists

NCT04313504 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which Niraparib is the first listed.

NCT04313504 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT04313504 about?

NCT04313504 is a clinical study titled "Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC". The purpose of this study is to determine the best overall response of the combination of dostarlimab and niraparib in patients with recurrent and/or metastatic HNSCC patients.

What is the current status of trial NCT04313504?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2020-11-04. Estimated completion is 2025-06-01.

What conditions does trial NCT04313504 study?

This clinical trial studies the following conditions: Head and Neck Cancer.

What interventions are being tested in trial NCT04313504?

The interventions under investigation include: Niraparib (DRUG), Dostarlimab (DRUG).

Who is sponsoring clinical trial NCT04313504?

This trial is sponsored by Trisha Wise-Draper, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04313504 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04313504's enrollment target sits among peer trials

23 210th of 250 higher than 38 of 250 other Head and Neck Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04313504, the US trial registry maintained by the National Library of Medicine. NCT04313504 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.